Strong Revenue Growth:
Revenue is growing at double-digit rates, with Q2 2026 up 27% year over year and first-half 2026 up about 25%. Management also raised full-year 2026 guidance to $94–96 million, implying approximately 22–24% growth.
Market Expansion:
U.S. activity accelerated, with U.S. analysis volume up 60% year over year in Q2 2026 and major health-system additions. Core genomics customers increased to 542 as of June 30, 2026, from 490 a year earlier.
Customer Loyalty & Retention:
Net dollar retention improved to 117% in Q2 2026 (versus 107% a year earlier), indicating greater spending within the installed base. Platform usage also reached a record 115,000 analyses in Q2 2026, up 22% year over year.
